Lavon Iris, Zrihan Daniel, Zelikovitch Bracha, Fellig Yakov, Fuchs Dana, Soffer Dov, Siegal Tali
Leslie and Michael Gaffin Center for Neuro-Oncology, Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel.
Clin Cancer Res. 2007 Mar 1;13(5):1429-37. doi: 10.1158/1078-0432.CCR-06-2050.
Because little is known about the evolution of genetic and epigenetic changes that occur during tumor progression in oligodendrogliomas, we evaluated these changes in paired early and progressive oligodendrogliomas.
1p36, 19q13, 10q22-26, and O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status were assessed in 46 paired early and progressive oligodendrogliomas from 23 patients.
In early tumors, 60.8% were of low grade compared with only 17% low-grade tumors at recurrence. Of 17 early tumors described as pure oligodendrogliomas, 76.5% remained in this lineage, regardless of their grade, whereas others changed to astrocytic tumors. Oligoastrocytic tumors had a significantly higher tendency to transform to astrocytic tumors. All pure oligodendrogliomas with 1p/19q codeletions remained phenotypically unchanged, unlike mixed tumors with codeletions, of which 83% changed their cell lineage. Of tumors with early 1p deletion, 80% remained oligodendroglial at progression, whereas 75% of tumors with an intact 1p changed to astrocytic phenotype. 10q loss was uncommon in both early and progressive tumors. The proportional gain in methylation at progression was 31% for tumors with early 1p deletion, unlike tumors with an intact 1p, which had an 87.5% gain of methylation at progression.
Pure oligodendrogliomas with 1p/19q deletion tend to retain their cell phenotype and genetic profile unlike tumors with no deletions or mixed histology. MGMT promoter methylation is more pronounced at tumor progression, particularly in tumors with an intact 1p. These observations suggest that MGMT promoter methylation is a late event in progressive oligodendrogliomas, and therefore, their chemosensitivity is not necessarily related to MGMT methylation status.
由于对少突胶质细胞瘤肿瘤进展过程中发生的基因和表观遗传变化的演变了解甚少,我们评估了配对的早期和进展期少突胶质细胞瘤中的这些变化。
对来自23例患者的46对配对的早期和进展期少突胶质细胞瘤评估了1p36、19q13、10q22 - 26以及O(6)-甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子甲基化状态。
在早期肿瘤中,60.8%为低级别,而复发时低级别肿瘤仅占17%。在17例被描述为纯少突胶质细胞瘤的早期肿瘤中,76.5%无论其级别如何均保持该细胞系,而其他肿瘤则转变为星形细胞瘤。少突星形细胞瘤转变为星形细胞瘤的趋势显著更高。所有具有1p/19q共缺失的纯少突胶质细胞瘤在表型上保持不变,与有共缺失的混合肿瘤不同,其中83%改变了细胞系。在早期有1p缺失的肿瘤中,80%在进展期仍为少突胶质细胞系,而1p完整的肿瘤中有75%转变为星形细胞表型。10q缺失在早期和进展期肿瘤中均不常见。进展期有早期1p缺失的肿瘤甲基化比例增加31%,而1p完整的肿瘤在进展期甲基化增加87.5%。
与无缺失或混合组织学的肿瘤不同,具有1p/19q缺失的纯少突胶质细胞瘤倾向于保留其细胞表型和基因谱。MGMT启动子甲基化在肿瘤进展时更为明显,尤其是在1p完整的肿瘤中。这些观察结果表明,MGMT启动子甲基化是进展期少突胶质细胞瘤中的晚期事件,因此它们的化学敏感性不一定与MGMT甲基化状态相关。